Reliability, validity, and minimally important differences of the SF-6D in systemic sclerosis

This publication has 42 references indexed in Scilit:

• Minimally important difference in diffuse systemic sclerosis: results from the d-penicillamine study
  Annals of the Rheumatic Diseases, 2006
• Systemic sclerosis: hypothesis-driven treatment strategies
  The Lancet, 2006
• Correlation of the degree of dyspnea with health‐related quality of life, functional abilities, and diffusing capacity for carbon monoxide in patients with systemic sclerosis and active alveolitis: Results from the scleroderma lung study
  Arthritis & Rheumatism, 2005
• Analysis and interpretation of health-related quality-of-life data from clinical trials: basic approach of The National Cancer Institute of Canada Clinical Trials Group
  European Journal Of Cancer, 2005
• A comparison of the EQ‐5D and SF‐6D across seven patient groups
  Health Economics, 2004
• Methods to Explain the Clinical Significance of Health Status Measures
  Mayo Clinic Proceedings, 2002
• The Disability Index of the Health Assessment Questionnaire is a predictor and correlate of outcome in the high-dose versus low-dose penicillamine in systemic sclerosis trial
  Arthritis & Rheumatism, 2001
• A power primer.
  Psychological Bulletin, 1992
• Measurement of health status
  Controlled Clinical Trials, 1989
• Measurement of patient outcome in arthritis
  Arthritis & Rheumatism, 1980